ASIT biotech Reintroduces an Application for Judicial Reorganization and Modifies the Composition of Its Board of Directors
20 Janvier 2020 - 12:49PM
Business Wire
Regulatory News:
ASIT biotech (BSE:ASIT) (Paris:ASIT) (ASIT -
BE0974289218), a clinical stage biopharmaceutical company
focused on the research and development of breakthrough
immunotherapy products for the treatment of allergies, was informed
by the Enterprise Court of Liège that certain information had to be
added to its request for judicial reorganization, as filed on 19
December 20191. To this end, a new request for reorganization by
collective agreement was filed today at the clerk's office of the
Enterprise Court of Liège2.
In addition, during the board of directors' meeting of January
16, 2020, Harry Welten and Jean-Paul Prieels informed the board of
directors of their intention to resign as directors at the next
general meeting of the company. Mr. Louis Champion, permanent
representative of ZOPAMAVI SAS, also submitted his resignation with
immediate effect. Mr. Yves Désiront, permanent representative of RE
FINANCE CONSULTING SA was appointed Chairman of the board of
directors in place of Mr. Louis Champion, permanent representative
of ZOPAMAVI SAS. There is no other change in the composition of the
board of directors, the list of members can be consulted on the
ASIT biotech website. On the other hand, the board of directors
confirmed the mandate of the management of ASIT biotech to explore
during the first semester of 2020 the strategic options to preserve
the interests of the creditors and shareholders to the maximum
extent possible.
*
About ASIT biotech
ASIT biotech is a Belgian clinical stage biopharmaceutical
company focused on the research and development of a range of
breakthrough immunotherapy products for the treatment of allergies.
Thanks to its innovative ASIT+' technology platform, ASIT biotech
is currently the only developer of allergy immunotherapy (AIT)
product candidates consisting of a unique mixture of highly
purified natural allergen fragments in an optimal size selection.
This innovation results in a short treatment, expected to improve
patient compliance and real-life effectiveness.
Further information can be found at www.asitbiotech.com
Follow us on LinkedIn
Legal notice
This announcement is for information purposes only and does not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe for the Company’s shares in any jurisdiction. This
announcement does not constitute a prospectus. Any purchase of,
subscription for or application for, Shares to be issued in
connection with the intended offering should only be made on the
basis of information contained in the prospectus and any
supplements thereto, as the case may be.
Forward-looking statements
This release may contain forward-looking statements. Such
forward-looking statements are not guaranteeing future results.
These forward-looking statements speak only as of the date of
publication of this document. The Company expressly disclaims any
obligation to update any forward-looking statements in this
document, unless specifically required by law or regulation.
---------
1 The document entitled "Judgment relating to the judicial
reorganization introduced on December 19, 2019" is available on the
website of ASIT biotech. 2 The document entitled "Request for
judicial reorganization by collective agreement" is available on
the website of ASIT biotech.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200120005227/en/
Michel Baijot, CEO ASIT biotech Tel.: +32 2 264 03 90
investors@asitbiotech.com